Science

Jul 13, 2025, 13:50

Myeloma Paper of the Day, July 13th, Suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day:

Sequential treatment with two different commercially approved BCMA CAR-T products (ide-cel -> cilta-cel) is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR-T therapy.”

Title: Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma

Authors: Tim Richardson, Udo Holtick, Jan Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias K Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christoph Scheid, Philipp Gödel

You can read the Full Article in Blood Advances.

Myeloma Paper of the Day, July 13th, Suggested by Robert Orlowski

You can find more posts featuring Robert Orlowski in OncoDaily.

BCMA BCMA CAR-T therapy cancer CAR-T Christoph Scheid Elias K. Mai Hishan Tharmaseelan Hyatt Balke-Want Jan Hendrik Frenking Malte von Bonin Michael Hallek MM Myeloma Myeloma Paper of the Day OncoDaily Oncology Philipp Gödel Raphael Teipel refractory multiple myeloma Robert Orlowski Ruth Flümann Sandra Sauer Tim Richardson Udo Holtick

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...